JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 90 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $19,869 | +66.7% | 10,740 | 0.0% | 0.00% | – |
| Q4 2022 | $11,921 | -79.8% | 10,740 | -57.2% | 0.00% | – |
| Q3 2022 | $59,000 | -24.4% | 25,115 | -2.3% | 0.00% | – |
| Q2 2022 | $78,000 | -71.1% | 25,715 | -35.2% | 0.00% | – |
| Q1 2022 | $270,000 | -13.7% | 39,712 | +6.1% | 0.00% | – |
| Q4 2021 | $313,000 | +11.8% | 37,435 | -0.7% | 0.00% | – |
| Q3 2021 | $280,000 | +9.8% | 37,685 | +0.7% | 0.00% | – |
| Q2 2021 | $255,000 | -37.2% | 37,435 | -5.2% | 0.00% | – |
| Q1 2021 | $406,000 | +40.5% | 39,485 | -4.3% | 0.00% | – |
| Q4 2020 | $289,000 | -16.7% | 41,260 | -3.0% | 0.00% | -100.0% |
| Q3 2020 | $347,000 | +16.4% | 42,535 | -1.5% | 0.00% | 0.0% |
| Q2 2020 | $298,000 | +46.8% | 43,195 | +1.1% | 0.00% | – |
| Q1 2020 | $203,000 | -13.2% | 42,730 | +59.2% | 0.00% | – |
| Q4 2019 | $234,000 | +207.9% | 26,840 | +17.7% | 0.00% | – |
| Q3 2019 | $76,000 | – | 22,795 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |